Compare Procter & Gamble Co (PG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Recursion Pharmaceuticals Inc — how do they compare? Procter & Gamble Co trades at $143.06 (market cap $338.13B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Procter & Gamble Co is far larger — about 181.8× Recursion Pharmaceuticals Inc's market cap, and Procter & Gamble Co pays a 2.99% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PG | RXRX | |
|---|---|---|
Market Cap | $338.13B | $1.86B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $6.79 |
52-Week Low | $138.10 | $2.84 |
Enterprise Value | $363.97B | $1.38B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters and maintains robust profitability with a net margin of 18.44% and ROE of 30.13%. Recent news highlights its dividend reliability and supply chain enhancements, while analyst consensus leans bullish with a $162.50 price target.
PG offers steady growth and income appeal with a 69-year dividend growth streak, but premium valuation and soft demand outlook pose near-term risks. Upside hinges on execution amid economic pressures, with support at $143 and resistance at $146.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
